Dominant-Negative SUN/KASH Proteins for LINC Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dilated cardiomyopathy (DCM) caused by LMNA mutations, such as heart transplantation, are ineffective and invasive, and there is a need for alternative methods to address the negative effects of over-accumulation of Sun1 protein in cells with Lmna mutations.
Innovation Solution
Disruption of the LINC complex by expressing dominant negative or mutated SUN and KASH domain proteins using expression vectors, such as AAV vectors with cardiac-specific promoters, to uncouple the nucleus from the cytoskeleton, thereby ameliorating laminopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heart transplantation is performed to treat LMNA-induced DCM, then patient survival is improved, but the treatment is invasive and does not address the underlying molecular mechanism
Solution Approach 1:
The invention extracts and removes the harmful LINC complex from the system by depleting SUN1 protein, which is responsible for the pathological coupling between the nucleus and cytoskeleton in LMNA-induced DCM. This allows treatment of the underlying molecular mechanism rather than just replacing the failed organ
Solution Approach 2:
The invention changes the molecular parameters within cardiomyocytes by introducing expression vectors that alter SUN1 protein levels or function, thereby modifying the pathological parameters of nuclear-cytoskeletal coupling without requiring external organ replacement
2Object-affected harmful factors
If SUN1 protein levels are reduced to treat laminopathy, then cytotoxic effects are ameliorated, but the approach may have off-target effects on normal nuclear-cytoskeletal coupling
Solution Approach 1:
The invention applies local quality by using cardiomyocyte-specific promoters (such as cTnT promoter) to drive expression of dominant-negative SUN domain proteins only in cardiomyocytes, thereby selectively affecting pathological processes in heart muscle cells while preserving normal functions in other cell types
Solution Approach 2:
The invention uses dominant-negative SUN domain proteins or mutated KASH domain proteins as intermediaries that specifically interfere with the pathological LINC complex formation caused by LMNA mutations, allowing selective disruption of harmful interactions while maintaining essential nuclear-cytoskeletal coupling functions
Data Source
AI summary
The present invention relates to use of expression vectors and other compounds in methods to disrupt the LInker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and/or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).